FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313360877> ?p ?o ?g. }

• W4313360877 endingPage "491" @default.
• W4313360877 startingPage "476" @default.
• W4313360877 abstract "Some studies have shown that sorafenib could significantly prolong the overall survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE). However, other studies revealed that patients had no access to sorafenib-related survival benefits after TACE. To identify the predictive biomarkers of therapeutic efficacy of sorafenib, we explored the potential predictive value of vascular endothelial growth factor (VEGF) and other clinical variables for survival benefits from sorafenib in patients treated with TACE previously. The results demonstrated that patients with tumor size > 7 cm or total bilirubin ≤ 17.3 μmol/L showed significant survival benefits from sorafenib after TACE treatment compared with those with tumor size ≤ 7 cm or total bilirubin > 17.3 μmol/L. Meanwhile, patients with VEGF > 131.09 pg/mL may obtain sorafenib-associated survival benefits after TACE when compared to those with VEGF ≤ 131.09 pg/mL, which needs further confirmation. The abovementioned results are helpful to confirm the specific population who are sensitive to targeted therapy. (1) Background: VEGF plays a crucial role in modulating proliferation and metastasis in HCC. We aimed to explore the relationship between VEGF and the prognosis, as well as the mortality risk of HCC patients who received TACE, and whether it and other variables could be considered as potential biomarkers for predicting the benefits from sorafenib. (2) Method: A total of 230 consecutive newly diagnosed patients with unresectable HCC treated with either TACE or TACE–sorafenib were collected retrospectively. Cox regression analyses were performed to evaluate the prognostic value of VEGF. Furthermore, restricted cubic splines were fitted to assess the nonlinear associations between VEGF and OS, and the threshold effect analysis was subsequently performed. Lastly, the potential factors for predicting the survival benefits from sorafenib after the TACE procedure were identified using the Cox proportional hazard model with an interaction term. (3) Results: VEGF was recognized as an independent prognostic factor for OS in the TACE alone cohort (HR = 3.237, p = 0.013). A nonlinear relationship was observed between VEGF and OS in HCC patients with TACE administration after adjustment for confounders (p for nonlinearity = 0.030); the mortality risk increased with increasing the baseline VEGF before the inflection point, and the HR for death was 1.008. There was no significant interaction between the VEGF levels and treatment modality (p for interaction = 0.233), and further studies are needed to identify its predictive value on the efficacy of sorafenib. Patients with tumor size > 7 cm or total bilirubin ≤ 17.3 μmol/L derived significant sorafenib-related benefits in OS when compared to those with tumor size ≤ 7 cm or total bilirubin > 17.3 μmol/L (p for interaction = 0.004 and 0.031, respectively). (4) Conclusions: Within a certain concentration range, elevated baseline VEGF meant an increased risk of death in HCC patients treated with TACE. Significant improvements in OS associated with sorafenib were observed in patients with higher tumor size and lower total bilirubin after TACE treatment." @default.
• W4313360877 created "2023-01-06" @default.
• W4313360877 creator A5021749487 @default.
• W4313360877 creator A5034433379 @default.
• W4313360877 creator A5052507660 @default.
• W4313360877 creator A5064708195 @default.
• W4313360877 creator A5080191032 @default.
• W4313360877 creator A5083378723 @default.
• W4313360877 creator A5085462851 @default.
• W4313360877 date "2022-12-29" @default.
• W4313360877 modified "2023-09-26" @default.
• W4313360877 title "Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization" @default.
• W4313360877 cites W1179082250 @default.
• W4313360877 cites W1633413258 @default.
• W4313360877 cites W1967922582 @default.
• W4313360877 cites W1971664385 @default.
• W4313360877 cites W1971837077 @default.
• W4313360877 cites W1975154077 @default.
• W4313360877 cites W1981224934 @default.
• W4313360877 cites W1989647054 @default.
• W4313360877 cites W1996229105 @default.
• W4313360877 cites W1997533142 @default.
• W4313360877 cites W2006206600 @default.
• W4313360877 cites W2022787071 @default.
• W4313360877 cites W2032171580 @default.
• W4313360877 cites W2048292172 @default.
• W4313360877 cites W2079077102 @default.
• W4313360877 cites W2079586464 @default.
• W4313360877 cites W2081557581 @default.
• W4313360877 cites W2084284022 @default.
• W4313360877 cites W2102942095 @default.
• W4313360877 cites W2106721500 @default.
• W4313360877 cites W2111070218 @default.
• W4313360877 cites W2141358606 @default.
• W4313360877 cites W2143045445 @default.
• W4313360877 cites W2151305493 @default.
• W4313360877 cites W2162741760 @default.
• W4313360877 cites W2222904843 @default.
• W4313360877 cites W2225797292 @default.
• W4313360877 cites W2286222994 @default.
• W4313360877 cites W2321700333 @default.
• W4313360877 cites W2496240332 @default.
• W4313360877 cites W2502891277 @default.
• W4313360877 cites W2583643739 @default.
• W4313360877 cites W2594017621 @default.
• W4313360877 cites W2661307008 @default.
• W4313360877 cites W2727497670 @default.
• W4313360877 cites W2762518662 @default.
• W4313360877 cites W2763700772 @default.
• W4313360877 cites W2767962371 @default.
• W4313360877 cites W2768662807 @default.
• W4313360877 cites W2889981809 @default.
• W4313360877 cites W2898929429 @default.
• W4313360877 cites W2903610058 @default.
• W4313360877 cites W2968989098 @default.
• W4313360877 cites W2996066981 @default.
• W4313360877 cites W3004536193 @default.
• W4313360877 cites W3008936374 @default.
• W4313360877 cites W3016546017 @default.
• W4313360877 cites W3025488590 @default.
• W4313360877 cites W3092715344 @default.
• W4313360877 cites W3109087664 @default.
• W4313360877 cites W3203259999 @default.
• W4313360877 cites W4232620598 @default.
• W4313360877 cites W4237081540 @default.
• W4313360877 cites W4282913388 @default.
• W4313360877 cites W4296026008 @default.
• W4313360877 doi "https://doi.org/10.3390/curroncol30010038" @default.
• W4313360877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36661687" @default.
• W4313360877 hasPublicationYear "2022" @default.
• W4313360877 type Work @default.
• W4313360877 citedByCount "0" @default.
• W4313360877 crossrefType "journal-article" @default.
• W4313360877 hasAuthorship W4313360877A5021749487 @default.
• W4313360877 hasAuthorship W4313360877A5034433379 @default.
• W4313360877 hasAuthorship W4313360877A5052507660 @default.
• W4313360877 hasAuthorship W4313360877A5064708195 @default.
• W4313360877 hasAuthorship W4313360877A5080191032 @default.
• W4313360877 hasAuthorship W4313360877A5083378723 @default.
• W4313360877 hasAuthorship W4313360877A5085462851 @default.
• W4313360877 hasBestOaLocation W43133608771 @default.
• W4313360877 hasConcept C121608353 @default.
• W4313360877 hasConcept C126322002 @default.
• W4313360877 hasConcept C143998085 @default.
• W4313360877 hasConcept C167734588 @default.
• W4313360877 hasConcept C2777025900 @default.
• W4313360877 hasConcept C2778019345 @default.
• W4313360877 hasConcept C2778455285 @default.
• W4313360877 hasConcept C2778695046 @default.
• W4313360877 hasConcept C2779013556 @default.
• W4313360877 hasConcept C2908647359 @default.
• W4313360877 hasConcept C3019894029 @default.
• W4313360877 hasConcept C50382708 @default.
• W4313360877 hasConcept C71924100 @default.
• W4313360877 hasConcept C90924648 @default.
• W4313360877 hasConcept C99454951 @default.
• W4313360877 hasConceptScore W4313360877C121608353 @default.
• W4313360877 hasConceptScore W4313360877C126322002 @default.

• next